Photo of Richard T. Penson,   MD MRCP

Richard T. Penson, MD MRCP

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-4800
Fax: (617) 724-6898


rpenson@partners.org

Richard T. Penson, MD MRCP

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Clinical Director Medical Gyneologic Oncology, Medicine, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Penson is the Clinical Director of Medical Gynecologic Oncology at Massachusetts General Hospital and Associate Professor at the Harvard Medical School. He sits on the national Gynecologic Oncology Group (GOG) committees for quality of life research, and the National Comprehensive Cancer Network (NCCN) committee for ovarian cancer. Dr. Penson serves as the chairman for two of the Institutional Review Board panels of Dana-Farber/Partners CancerCare, and is very actively involved in the investigation of novel agents and treatment strategies in ovarian cancer, and psychosocial issues related to gynecologic cancer care and general oncology.

Publications

Powered by Harvard Catalyst
  • Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol 2015. PubMed
  • Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Method M, Michael H, Tewari KS. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015; 16:301-11. PubMed
  • Schorge JO, Clark RM, Lee SI, Penson RT. Primary debulking surgery for advanced ovarian cancer: Are you a believer or a dissenter? Gynecol Oncol 2014. PubMed
  • Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol 2014; 134:478-85. PubMed
  • Donovan KA, Donovan HS, Cella D, Gaines ME, Penson RT, Plaxe SC, von Gruenigen VE, Bruner DW, Reeve BB, Wenzel L. Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. Journal of the National Cancer Institute 2014. PubMed
  • Ambrosio AJ, Suzin D, Palmer EL, Penson RT. Vintafolide (EC145) for the treatment of folate-receptor-留 positive platinum-resistant ovarian cancer. Expert Rev Clin Pharmacol 2014. PubMed
  • Schapira L, Blaszkowsky LS, Cashavelly BJ, Kim CY, Riley JP, Wold MC, Ryan DP, Penson RT. Caring for One of Our Own. Oncologist 2014. PubMed
  • George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer 2014; 120:738-43. PubMed
  • Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370:734-43. PubMed
  • Peterson VM, Castro CM, Chung J, Miller NC, Ullal AV, Castano MD, Penson RT, Lee H, Birrer MJ, Weissleder R. Ascites analysis by a microfluidic chip allows tumor-cell profiling. Proc Natl Acad Sci U S A 2013; 110:E4978-86. PubMed
  • Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 2013; 31:4400-6. PubMed
  • Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw 2013; 11:1199-209. PubMed
  • Penson RT, Goodman A, Growdon WB, Borger DR, Lee SI, Oliva E. Case records of the Massachusetts General Hospital. Case 14-2013. A 70-year-old woman with vaginal bleeding. N Engl J Med 2013; 368:1827-35. PubMed
  • Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian Cancer, Version 3.2012. J Natl Compr Canc Netw 2012; 10:1339-1349. PubMed
  • Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol 2012. PubMed
  • Dizon DS, Damstrup L, Finkler NJ, Lassen U, Celano P, Glasspool R, Crowley E, Lichenstein HS, Knoblach P, Penson RT. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int J Gynecol Cancer 2012; 22:979-86. PubMed
  • Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-留5硫1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 2011. PubMed
  • Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL. Epithelial ovarian cancer. J Natl Compr Canc Netw 2011; 9:82-113. PubMed
  • Kornblith AB, Mirabeau-Beale K, Lee H, Goodman AK, Penson RT, Pereira L, Matulonis UA. Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease. J Psychosoc Oncol 2010; 28:451-69. PubMed
  • Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376:245-51. PubMed
  • Dean-Clower E, Doherty-Gilman AM, Keshaviah A, Baker F, Kaw C, Lu W, Manola J, Penson RT, Matulonis UA, Rosenthal DS. Acupuncture as Palliative Therapy for Physical Symptoms and Quality of Life for Advanced Cancer Patients. Integr Cancer Ther 2010; 9:158-67. PubMed
  • Young RH, Goodman A, Penson RT, Russell AH, Uppot RN, Tambouret RH. Case records of the Massachusetts General Hospital. Case 8-2010. A 22-year-old woman with hypercalcemia and a pelvic mass. N Engl J Med 2010; 362:1031-40. PubMed
  • Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol 2010; 5:477-83. PubMed
  • Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT. Phase II trial of GM-CSF in women with asymptomatic recurrent m端llerian tumors. Gynecol Oncol 2010; 116:168-72. PubMed
  • Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2009; 28:154-9. PubMed
  • Penson RT, Schapira L, Mack S, Stanzler M, Lynch TJ. Connection: schwartz center rounds at massachusetts general hospital cancer center. Oncologist 2010; 15:760-4. PubMed
  • Na YJ, Farley J, Zeh A, del Carmen M, Penson R, Birrer MJ. Ovarian cancer: markers of response. Int J Gynecol Cancer 2009; 19 Suppl 2:S21-9. PubMed
  • Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27:5601-6. PubMed
  • Mirabeau-Beale KL,Kornblith AB,Penson RT,Lee H,Goodman A,Campos SM,Duska L,Pereira L,Bryan J,Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol 2009; 114:353-9. PubMed
  • Lu W, Matulonis UA, Doherty-Gilman A, Lee H, Dean-Clower E, Rosulek A, Gibson C, Goodman A, Davis RB, Buring JE, Wayne PM, Rosenthal DS, Penson RT. Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med 2009; 15:745-53. PubMed
  • Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 2009; 123:1262-7.e1. PubMed
  • Koulouris CR,Penson RT. Ovarian stromal and germ cell tumors. Semin Oncol 2009; 36:126-36. PubMed
  • Penson RT. Sugar fuels cancer. Cancer 2009; 115:918-21. PubMed
  • Matulonis UA,Krag KJ,Krasner CN,Atkinson T,Horowitz NS,Lee H,Penson RT. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecol Oncol 2008; 112:394-9. PubMed
  • Matulonis UA,Horowitz NS,Campos SM,Lee H,Lee J,Krasner CN,Berlin S,Roche MR,Duska LR,Pereira L,Kendall D,Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2008; 26:5761-6. PubMed
  • Olawaiye AB,Morgan JA,Goodman A,Fuller AF Jr,Penson RT. Epithelioid angiosarcoma of the uterus: a review of management. Arch Gynecol Obstet 2008; 278:401-4. PubMed
  • Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180-6. PubMed
  • Abrams AN, Hazen EP, Penson RT. Psychosocial issues in adolescents with cancer. Cancer Treat Rev 2007; 33:622-30. PubMed
  • Penson RT, Gu F, Harris S, Thiel MM, Lawton N, Fuller AF Jr, Lynch TJ Jr. Hope. Oncologist 2007; 12:1105-13. PubMed
  • Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV, ,. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced mlerian malignancies: The modified triple doublet regimen. Gynecol Oncol 2006; 103:575-80. PubMed
  • Penson RT, Wenzel LB, Vergote I, Cella D. Quality of life considerations in gynecologic cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S247-57. PubMed
  • Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A,. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol 2006; 103:160-4. PubMed
  • Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire WP. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol 2005; 101:55-61. PubMed
  • Abel GA, Penson RT, Joffe S, Schapira L, Chabner BA, Lynch TJ. Direct-to-consumer advertising in oncology. Oncologist 2006; 11:217-26. PubMed
  • Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage 2005; 30:563-9. PubMed
  • Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA,. A phase II study of fixed dose rate gemcitabine in patients with relapsed mlerian tumors. Int J Gynecol Cancer 2005; 15:1035-41. PubMed
  • Penson RT, Seiden MV. Topotecan: weighing in when there are many options. Oncologist 2005; 10:698-700. PubMed
  • Penson RT, Partridge RA, Rudd P, Seiden MV, Nelson JE, Chabner BA, Lynch TJ. Laughter: the best medicine? Oncologist 2005; 10:651-60. PubMed
  • Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. Br J Cancer 2005; 93:54-9. PubMed
  • Wolpin BM, Chabner BA, Lynch TJ, Penson RT. Learning to cope: how far is too close? Oncologist 2005; 10:449-56. PubMed
  • Penson RT, Joel SP, Gloyne A, Clark S, Slevin ML. Morphine analgesia in cancer pain: role of the glucuronides. J Opioid Manag 2007; 1:83-90. PubMed
  • Penson RT, Partridge RA, Shah MA, Giansiracusa D, Chabner BA, Lynch TJ. Fear of death. Oncologist 2005; 10:160-9. PubMed
  • Lee MS, Gupta N, Penson RT, Loewenstein J, Wepner MS, Seiden MV, Milam AH. Cone damage in patients receiving high-dose irofulven treatment. Arch Ophthalmol 2005; 123:29-34. PubMed
  • Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 2004; 95:624-31. PubMed
  • Penson RT, Dignan F, Seiden MV, Lee H, Gallagher CJ, Matulonis UA, Olson K, Gibbens I, Gore ME. Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol 2004; 94:427-35. PubMed
  • Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM,. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with mlerian malignancies. Gynecol Oncol 2004; 93:702-7. PubMed
  • Nouriani M, Bahador A, Berek JS, Cheng JP, Chi DS, Cliby WA, Del Priore G, Dodson MK, Duggan BD, Gershenson DM, Lentz SE, Penson RT, Robinson WR, Rodriguez M, Roman LD, Yu MC, Zempolich K, Dubeau L. Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Clin Cancer Res 2004; 10:2681-6. PubMed
  • Penson RT, Amrein PC. Faith and freedom: leukemia in Jehovah Witness minors. Onkologie 2004; 27:126-8. PubMed
  • Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF, Goodman A, Seiden MV. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 2004; 93:98-106. PubMed
  • Penson RT, Daniels KJ, Lynch TJ. Too old to care? Oncologist 2004; 9:343-52. PubMed
  • Penson RT, Talsania SH, Chabner BA, Lynch TJ. Help me help you: support groups in cancer therapy. Oncologist 2004; 9:217-25. PubMed
  • del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV. Phase II trial of anastrozole in women with asymptomatic mlerian cancer. Gynecol Oncol 2003; 91:596-602. PubMed
  • Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF, Wilson KS, Puchalski TA, Supko JG, Seiden MV. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mlerian tumors. Gynecol Oncol 2003; 90:610-8. PubMed
  • Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 2003; 9:2778-85. PubMed
  • Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003; 3:1-19. PubMed
  • Penson RT, Nunn C, Younger J, Schaeffer NJ, Chabner BA, Fricchione GL, Quinn TE, Lynch TJ. Trust violated: analgesics for addicts. Oncologist 2003; 8:199-209. PubMed
  • Penson RT, Fergus LA, Haston RJ, Clark JR, Demotses A, O'Connell JJ, Chabner BA, Lynch TJ. The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless. Oncologist 2003; 8:488-95. PubMed
  • Dias L, Chabner BA, Lynch TJ, Penson RT. Breaking bad news: a patient's perspective. Oncologist 2003; 8:587-96. PubMed
  • Lamendola DE, Duan Z, Penson RT, Oliva E, Seiden MV. beta tubulin mutations are rare in human ovarian carcinoma. Anticancer Res 2003; 23:681-6. PubMed
  • Knuti KA, Wharton RH, Wharton KL, Chabner BA, Lynch TJ, Penson RT. Living as a cancer surpriser: a doctor tells his story. Oncologist 2003; 8:108-22. PubMed
  • Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, Seiden MV. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 2002; 22:1933-41. PubMed
  • Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed mlerian tumors of the ovary. Gynecol Oncol 2002; 85:459-63. PubMed
  • Penson RT, Joel SP, Roberts M, Gloyne A, Beckwith S, Slevin ML. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. Br J Clin Pharmacol 2002; 53:347-54. PubMed
  • Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine 2002; 17:234-42. PubMed
  • Knuti KA, Amrein PC, Chabner BA, Lynch TJ, Penson RT. Faith, identity, and leukemia: when blood products are not an option. Oncologist 2002; 7:371-80. PubMed
  • Penson RT, Green KM, Chabner BA, Lynch TJ. When does the responsibility of our care end: bereavement. Oncologist 2002; 7:251-8. PubMed
  • Penson RT, Benson RC, Parles K, Chabner BA, Lynch TJ. Virtual connections: Internet health care. Oncologist 2002; 7:555-68. PubMed
  • Penson RT, Rauch PK, McAfee SL, Cashavelly BJ, Clair-Hayes K, Dahlin C, Green KM, Chabner BA, Lynch TJ. Between parent and child: negotiating cancer treatment in adolescents. Oncologist 2002; 7:154-62. PubMed
  • Penson RT, Joel SP, Clark S, Gloyne A, Slevin ML. Limited phase I study of morphine-3-glucuronide. J Pharm Sci 2001; 90:1810-6. PubMed
  • Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Mlerian tumors. Cancer 2001; 92:1156-67. PubMed
  • Penson RT, Fuller AF. Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva. J Clin Oncol 2001; 19:2767-8. PubMed
  • Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001; 81:206-12. PubMed
  • Penson RT, Fuller AF. Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva. J Clin Oncol 2001; 19:2364-5. PubMed
  • Penson RT, Castro CM, Seiden MV, Chabner BA, Lynch TJ. Complementary, alternative, integrative, or unconventional medicine? Oncologist 2001; 6:463-73. PubMed
  • Penson RT, Yusuf RZ, Chabner BA, Lafrancesca JP, McElhinny M, Axelrad AS, Lynch TJ. Losing God. Oncologist 2001; 6:286-97. PubMed
  • Mulatero CW, Penson RT, Papamichael D, Gower NH, Evans M, Rudd RM. A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 2001; 31:67-72. PubMed
  • Penson RT, Seiden MV, Chabner BA, Lynch TJ. Caring for colleagues. Oncologist 2001; 6:197-204. PubMed
  • Penson RT, Svendsen SS, Chabner BA, Lynch TJ, Levinson W. Medical mistakes: a workshop on personal perspectives. Oncologist 2001; 6:92-9. PubMed
  • Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML. Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 2001; 68:667-76. PubMed
  • Feller AJ, Duan Z, Penson R, Toh HC, Seiden MV. TRAG-3, a novel cancer/testis antigen, is overexpressed in the majority of melanoma cell lines and malignant melanoma. Anticancer Res 2001; 20:4147-51. PubMed
  • Cook S, Penson R, Duska L, Nikrui N, Goodman A, Fuller A, Seiden M. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer. Gynecol Oncol 2000; 77:48-54. PubMed
  • Krakauer EL, Penson RT, Truog RD, King LA, Chabner BA, Lynch TJ. Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect. Oncologist 2000; 5:53-62. PubMed
  • Penson RT, Gallagher J, Gioiella ME, Wallace M, Borden K, Duska LA, Talcott JA, McGovern FJ, Appleman LJ, Chabner BA, Lynch TJ. Sexuality and cancer: conversation comfort zone. Oncologist 2000; 5:336-44. PubMed
  • Penson RT, Seiden MV, Shannon KM, Lubratovich ML, Roche M, Chabner BA, Lynch TJ. Communicating genetic risk: pros, cons, and counsel. Oncologist 2000; 5:152-61. PubMed
  • Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, Lee J, Sullivan L, Penson R. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer 2009; 18:1183-93. PubMed
  • Penson RT, Dignan FL, Canellos GP, Picard CL, Lynch TJ. Burnout: caring for the caregivers. Oncologist 2000; 5:425-34. PubMed
  • Penson RT. Ovarian Cancer 2007.
  • Penson RT. Cycles within cycles. Menopause 2008; 15:412-3. PubMed
  • Wenzel L, Penson RT, Carter J, Chase D, Cella D. Quality of Life Issues in Gynecologic Oncology 2009.
  • Rauh-Hain JA, Penson RT. Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 2008; 18:934-6. PubMed
  • Audeh MW, Penson RT. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer J Clin Oncol 2009.
  • Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 1999; 5:3445-53. PubMed
  • Penson RT, Skates SJ, Fuller AJ, Seiden MV. Clinical course of stage IV epithelial ovarian cancer. J Clin Oncol 1999; 17:3361-2. PubMed
  • Ryan DP, Penson RT, Ahmed S, Chabner BA, Lynch TJ. Reality testing in cancer treatment: the phase I trial of endostatin. Oncologist 2000; 4:501-8. PubMed
  • Penson RT, Seiden MV. Progress in gynecologic oncology. Oncologist 1999; 4:293-8. PubMed
  • O'Shea EM, Lintz KC, Penson RT, Seiden MV, Chabner BA, Lynch TJ. A staff dialogue on caring for a cancer patient who commits suicide: psychosocial issues faced by patients, their families, and caregivers. Oncologist 1999; 4:122-7. PubMed
  • O'Shea EM, Penson RT, Stern TA, Younger J, Chabner BA, Lynch TJ. A staff dialogue on do not resuscitate orders: psychosocial issues faced by patients, their families, and caregivers. Oncologist 1999; 4:256-62. PubMed
  • Lintz KC, Penson RT, Cassem N, Harmon DC, Chabner BA, Lynch TJ. A staff dialogue on aggressive palliative treatment demanded by a terminally ill patient: psychosocial issues faced by patients, their families, and caregivers. Oncologist 1999; 4:70-6. PubMed
  • Goodman A, Penson RT, Blatman R, McIntyre J, Gioiella ME, Chabner BA, Lynch TJ. A staff dialogue on a socially distanced patient: psychosocial issues faced by patients, their families, and caregivers. Oncologist 1999; 4:417-24. PubMed
  • Papamichael D, Seymour MT, Penson RT, Wilson P, Gallagher CJ, Besser GM, Slevin ML. Double modulation of 5-fluorouracil with interferon alpha-2a and high-dose leucovorin in advanced neuroendocrine tumours. Eur J Cancer 1999; 34:2133-4. PubMed
  • Penson RT, Shannon KE, Sharpless NE, Seiden MV. Ovarian cancer: an update on genetics and therapy. Compr Ther 1998; 24:477-87. PubMed
  • Lintz KC, Penson RT, Chabner BA, Mack S, Lynch TJ. Schwartz Center Rounds. A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist 1999; 3:357-364. PubMed
  • Lintz KC, Penson RT, Chabner BA, Lynch TJ. Schwartz Center Rounds. A Staff Dialogue on Caring for an Intensely Spiritual Patient: Psychosocial Issues Faced By Patients, Their Families, and Caregivers. Oncologist 1999; 3:439-445. PubMed
  • Penson RT, Rudd RM. Poor recruitment to lung cancer trials. BMJ 1997; 314:974-5. PubMed
  • Penson RT, Rudd RM. Commentary: octreotide and hypertrophic pulmonary osteoarthropathy. Thorax 1997; 52:297-8. PubMed
Hide